Forgent Power Solutions Inc. Class A Common Stock vs IDEXX Laboratories, Inc. — how do they compare? Forgent Power Solutions Inc. Class A Common Stock trades at $31.97 (market cap $9.93B), while IDEXX Laboratories, Inc. trades at $532.96 (market cap $40.99B). The key difference: IDEXX Laboratories, Inc. is far larger — about 4.1× Forgent Power Solutions Inc. Class A Common Stock's market cap, and IDEXX Laboratories, Inc. is more actively traded (445,410 versus 7,516,726). Which is the better fit depends on your goals — on Pluang, investors hold Forgent Power Solutions Inc. Class A Common Stock for 0 Days and IDEXX Laboratories, Inc. for 47 Days on average.
| FPS | IDXX | |
|---|---|---|
Market Cap | $9.93B | $40.99B |
Volume | 7,516,726 | 445,410 |
Sector | Industrials | Health |
52-Week High | $64.59 | $766.68 |
52-Week Low | $27.97 | $504.70 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $10.54B | $41.89B |
Signals from Pluang's Aura AI — not financial advice
Forgent Power Solutions (FPS) trades at $36.17, down 2.48% on the day, following a strong earnings-driven rally. The stock shows neutral technical signals with support at $35 and resistance at $37. Recent Q2 2026 earnings beat expectations with EPS of $0.25 versus $0.24 expected, continuing a pattern of quarterly outperformance. The company reported record $3 billion backlog and strong data center demand driving growth.
FPS presents significant upside potential with analyst consensus target of $55.20 (52.9% upside) and 85.7% buy ratings. However, high valuation multiples (P/E 120.57, P/S 6.21) and negative 2025 net income of -$6.17M create valuation concerns. Key risks include execution on $3B backlog and potential overvaluation amid AI infrastructure hype.
IDEXX Laboratories (IDXX) trades at $529.01, up 0.97% with strong fundamental performance including 25.03% net income margin and consistent earnings beats. The stock shows neutral technical signals with support at $518 and resistance at $528. Recent acquisitions like CoVetAI and diagnostic platform expansions demonstrate strategic growth initiatives. Revenue grew from $3.9B in 2024 to $4.3B in 2025 with profit margins expanding to 24.61%.
Outlook remains positive with 56.5% analyst buy ratings and $665 consensus price target representing 25.7% upside. Key risks include FX headwinds and weaker U.S. vet visits, but strong recurring revenue and diagnostic innovation pipeline support long-term growth framework. The company's premium valuation (P/E 36.56) reflects market confidence in sustained profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Forgent Power Solutions designs and manufactures electrical distribution equipment, including transformers, switchgear, transfer switches, and prefabricated power systems, for data centers, the power grid, and industrial facilities, manufacturing across multiple product categories in-house through a network of manufacturing campuses in US.
Read more on FPS →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →